Editas Medicine Inc
EDIT
ISIN null / Valor 30992799
Editas Medicine Inc
UMushroom community rating:
About company
Editas Medicine Inc is a gene editing company that specializes in developing genomic medicines for a range of diseases using CRISPR gene editing technology. The company's proprietary SLEEK gene editing approach enables high efficiency, multi-transgene knock-in of induced pluripotent stem cells, T cells, and natural killer cells, ensuring robust transgene expression. Editas Medicine works with CRISPR nucleases, including Cas9 and Cas12a, to revise, remove, and replace DNA in a highly targeted manner. The company sees CRISPR as a versatile platform technology with the potential to develop medicines for a wide variety of diseases by targeting DNA in any cell or tissue.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
199 M
Market cap (USD)
1,663,299
Daily traded volume (Shares)
1.265 / 1.175
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Marc Bareth
EQUITIES OF THE SAME SECTOR
